Compare AU

Compare CURE vs. A200

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the Aussie 200 Large-Caps (A200). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

A200

Popularity

Low

Medium

Pearlers invested

82

4,953

Median incremental investment

$619.50

$1,078.59

Median investment frequency

Monthly

Monthly

Median total investment

$1,290.82

$3,652.29

Average age group

> 35

26 - 35


Key Summary

CURE

A200

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

BetaShares Australia 200 ETF (ASX: A200) seeks to track the performance of the Solactive Australia 200 index before account fees, expenses, and taxes. The index tracks the largest 200 companies on the Australian Securities Exchange (ASX).

Top 3 holdings

Natera Inc (3.41 %)

Incyte Corp (2.94 %)

Gilead Sciences Inc (2.88 %)

COMMONWEALTH BANK OF AUSTRALIA (10.93 %)

BHP GROUP LTD (8.29 %)

CSL LTD (5.65 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (33.91 %)

Materials (17.89 %)

Health Care (8.74 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (95.07 %)

United States (3.04 %)

New Zealand (1.41 %)

Management fee

0.45 %

0.04 %


Key Summary

CURE

A200

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Solactive Australia 200 Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.04 %

Price

$49.94

$137.57

Size

$38.065 million

$6.279 billion

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

5.25 %

Market

ASX

ASX

First listed date

12/11/2018

08/05/2018

Purchase fee

$6.50

$6.50


Community Stats

CURE

A200

Popularity

Low

Medium

Pearlers invested

82

4,953

Median incremental investment

$619.50

$1,078.59

Median investment frequency

Monthly

Monthly

Median total investment

$1,290.82

$3,652.29

Average age group

> 35

26 - 35


Pros and Cons

CURE

A200

Pros

  • Higher exposure to US market

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

  • Lower exposure to US market

CURE

A200

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home